FMFrederick Monsma

Frederick Monsma

*This is an algorithmically generated author record based on publicly available information.

Frederick Monsma has a total of 202 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Modeling of Intracellular Taurine Levels Associated with Ovarian Cancer Reveals Activation of p53, ERK, mTOR and DNA-Damage-Sensing-Dependent Cell Protection

    by Daniel Centeno, Sadaf Farsinejad, Elena Kochetkova, Tatiana Volpari, Aleksandra Gladych-Macioszek, Agnieszka Klupczynska-Gabryszak, Teagan Polotaye, Michael Greenberg, Douglas Kung, Emily Hyde, et al.

    Taurine, a non-proteogenic amino acid and commonly used nutritional supplement, can protect various tissues from degeneration associated with the action of the DNA-damaging chemotherapeutic agent cisplatin. Whether and how taurine protects human ovarian cancer (OC) cells from DNA damage caused by cisplatin is not well understood. We found that OC ascites-derived cells contained significantly more intracellular taurine than cell culture-modeled OC. In culture, elevation of intracellular taurine concentration to OC ascites-cell-associated levels suppressed proliferation of various OC cell lines and patient-derived organoids, reduced glycolysis, and induced cell protection from cisplatin. Taurine cell protection was associated with decreased DNA damage in response to cisplatin. A combination of RNA sequencing, reverse-phase protein arrays, live-cell microscopy, flow cytometry, and biochemical validation experiments provided evidence for taurine-mediated induction of mutant or wild-type p53 binding to DNA, activation of p53 effectors involved in negative regulation of the cell cycle (p21), and glycolysis (TIGAR). Paradoxically, taurine’s suppression of cell proliferation was associated with activation of pro-mitogenic signal transduction including ERK, mTOR, and increased mRNA expression of major DNA damage-sensing molecules such as DNAPK, ATM and ATR. While inhibition of ERK or p53 did not interfere with taurine’s ability to protect cells from cisplatin, suppression of mTOR with Torin2, a clinically relevant inhibitor that also targets DNAPK and ATM/ATR, broke taurine’s cell protection. Our studies implicate that elevation of intracellular taurine could suppress cell growth and metabolism, and activate cell protective mechanisms involving mTOR and DNA damage-sensing signal transduction.


  • Open Access

    Integrating deep learning and unbiased automated high-content screening to identify complex disease signatures in human fibroblasts

    by Lauren Schiff, Bianca Migliori, Ye Chen, Deidre Carter, Caitlyn Bonilla, Jenna Hall, Minjie Fan, Edmund Tam, Sara Ahadi, Brodie Fischbacher, et al.

    Drug discovery for diseases such as Parkinson’s disease are impeded by the lack of screenable cellular phenotypes. We present an unbiased phenotypic profiling platform that combines automated cell culture, high-content imaging, Cell Painting, and deep learning. We applied this platform to primary fibroblasts from 91 Parkinson’s disease patients and matched healthy controls, creating the largest publicly available Cell Painting image dataset to date at 48 terabytes. We use fixed weights from a convolutional deep neural network trained on ImageNet to generate deep embeddings from each image and train machine learning models to detect morphological disease phenotypes. Our platform’s robustness and sensitivity allow the detection of individual-specific variation with high fidelity across batches and plate layouts. Lastly, our models confidently separate LRRK2 and sporadic Parkinson’s disease lines from healthy controls (receiver operating characteristic area under curve 0.79 (0.08 standard deviation)), supporting the capacity of this platform for complex disease modeling and drug screening applications.


  • Open Access

    HIV Cell Fusion Assay: Phenotypic Screening Tool for the Identification of HIV Entry Inhibitors via CXCR4

    by Elizabeth B. Smith, Robert A. Ogert, David Pechter, Artjohn Villafania, Susan J. Abbondanzo, Karen Lin, Aida Rivera-Gines, Cheryl Rebsch-Mastykarz, Jr. Frederick J. Monsma


  • Murgocil is a Highly Bioactive Staphylococcal-Specific Inhibitor of the Peptidoglycan Glycosyltransferase Enzyme MurG

    by Paul A. Mann, Anna Müller, Li Xiao, Pedro M. Pereira, Christine Yang, Sang Ho Lee, Hao Wang, Joanna Trzeciak, Jonathan Schneeweis, Margarida Moreira dos Santos, et al.

    Modern medicine is founded on the discovery of penicillin and subsequent small molecules that inhibit bacterial peptidoglycan (PG) and cell wall synthesis. However, the discovery of new chemically and mechanistically distinct classes of PG inhibitors has become exceedingly rare, prompting speculation that intracellular enzymes involved in PG precursor synthesis are not ‘druggable’ targets. Here, we describe a β-lactam potentiation screen to identify small molecules that augment the activity of β-lactams against methicillin-resistant Staphylococcus aureus (MRSA) and mechanistically characterize a compound resulting from this screen, which we have named murgocil. We provide extensive genetic, biochemical, and structural modeling data demonstrating both in vitro and in whole cells that murgocil specifically inhibits the intracellular membrane-associated glycosyltransferase, MurG, which synthesizes the lipid II PG substrate that penicillin binding proteins (PBPs) polymerize and cross-link into the cell wall. Further, we demonstrate that the chemical synergy and cidality achieved between murgocil and the β-lactam imipenem is mediated through MurG dependent localization of PBP2 to the division septum. Collectively, these data validate our approach to rationally identify new target-specific bioactive β-lactam potentiation agents and demonstrate that murgocil now serves as a highly selective and potent chemical probe to assist our understanding of PG biosynthesis and cell wall biogenesis across Staphylococcal species.


  • SCH 1473759, a novel Aurora inhibitor, demonstrates enhanced anti-tumor activity in combination with taxanes and KSP inhibitors

    by Andrea D. Basso, Ming Liu, Kimberly Gray, Seema Tevar, Suining Lee, Lianzhu Liang, Abdul Ponery, Elizabeth B. Smith, Frederick J. Monsma, Tao Yu, et al.

    Aurora kinases are required for orderly progression of cells through mitosis, and inhibition of these kinases by siRNA or small molecule inhibitors results in cell death. We previously reported the synthesis of SCH 1473759, a novel sub-nanomolar Aurora A/B inhibitor.


  • Binding kinetics and mechanism of action: toward the discovery and development of better and best in class drugs

    by Rumin Zhang, Frederick Monsma

    Binding kinetics (BK), an often overlooked key aspect of the broader concept of drug mechanism of action (MOA), is increasingly recognized as a springboard from pharmacokinetics (PK) to pharmacodynamics, and as a critical differentiator and predictor for drug efficacy and safety. Just as greater attention to PK issues has helped reduce the attrition of drugs tested in clinical trials, the emerging paradigm shift from primarily affinity/potency-emphasized to a more holistic BK-perceptive and MOA-informed approach is expected to further enhance the success of drug discovery and development. This perspective attempts to envision what this new approach looks like when proper emphasis is placed on BK and MOA in designing better and best in class drugs.


    • 1 July 2010
      • Vol. 13  (4) , 389-402

    Fluorescence-based thermal shift assays.

    by Rumin Zhang, Frederick Monsma

    Thermal shift assays are one of the label-free technologies gaining popularity in drug discovery and academic research. This review summarizes the various detection formats used in these assays, and provides an in-depth presentation of fluorescence-based thermal shift assays. The dual applications of stability profiling and affinity ranking are highlighted, and basic experimental protocol and data analysis algorithms are recommended. The advantages and limitations of the technology are also discussed to provide guidance for meaningful data interpretation. In addition, an emerging paradigm is described that incorporates thermal shift assays with other label-free biosensors and conventional IC(50) assays to derive a mechanism of action-informed SAR in lead identification and optimization during drug discovery.


  • Open Access

    Screening for Antibacterial Inhibitors of the UDP-3-O-(R-3-Hydroxymyristoyl)-N-Acetylglucosamine Deacetylase (LpxC) Using a High-Throughput Mass Spectrometry Assay

    by Erik F. Langsdorf, Asra Malikzay, William A. Lamarr, Dayna Daubaras, Cynthia Kravec, Rumin Zhang, Richard Hart, Frederick Monsma, Todd Black, Can C. Ozbal, et al.


    • 1 July 2009
      • Vol. 12  (4) , 488-96

    The importance of drug-target residence time.

    by Rumin Zhang, Frederick Monsma

    The importance of kinetics in drug-target interactions, and particularly the residence time of a drug with its target, is increasingly recognized to play a pivotal role in determining both the efficacy and toxicity of a drug. Drug residence time can often be demonstrated to be a key differentiating factor between drugs that act upon a common target. Drug-target residence time can result in either favorable or unfavorable outcomes, and the use of such information could lead to the more efficient design of best-in-class drugs. This review highlights several key concepts and observations related to drug-target residence time, and suggests the use of a kinetics-perceptive and energetics-informed approach to address the challenges facing current drug discovery efforts.


  • Open Access

    Short-chain fatty acids act as antiinflammatory mediatorsby regulating prostaglandin E2 and cytokines

    by Mary Ann Cox, James Jackson, Michaela Stanton, Alberto Rojas-Triana, Loretta Bober, Maureen Laverty, Xiaoxin Yang, Feng Zhu, Jianjun Liu, Suke Wang, et al.

    Short-chain fatty acids act as antiinflammatory mediators by regulating prostaglandin E2 and cytokines